Our study results demonstrate the potential of vinpocetine in treating MetS-associated OABs by restoring the succinate-modulated detrusor cAMP levels and exerting anti-inflammatory effects in the detrusor muscle, contributing to the beneficial effect of the PDE inhibitor on the micturition behaviours and detrusor functions in FFRs. The gene discussed is ALDH7A1; the disease is metabolic syndrome.